Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Senti Biosciences. The associated price target remains the same with $12.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on the promising clinical data from Senti Biosciences’ ongoing Phase 1 trial of SENTI-202 in patients with relapsed or refractory acute myeloid leukemia (AML). The trial results showed a favorable overall response rate of 50% and a complete response rate of 39%, with a median durability of response estimated at 7.6 months. These outcomes, alongside the RMAT designation granted to SENTI-202, suggest a strong potential for the therapy in treating AML, particularly given the consistency of results across updates.
Additionally, the safety profile of SENTI-202 appears favorable, with most adverse events being manageable and related to lymphodepletion rather than the therapy itself. The low toxicity profile compared to other cell therapies supports the potential for SENTI-202 to be used in earlier lines of AML treatment. These factors combined with the company’s plans to engage with the FDA for a pivotal program in 2026, contribute to the Buy rating, as they indicate a positive outlook for Senti Biosciences’ future developments.
In another report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $13.00 price target.